PubMed

Virologic failure in therapy-naive subjects on aplaviroc plus lopinavir-ritonavir: detection of aplaviroc resistance requires clonal analysis of envelope.

Kitrinos KM, Amrine-Madsen H, Irlbeck DM, Word JM, Demarest JF; CCR100136 Study Team.

Antimicrob Agents Chemother. 2009 Mar;53(3):1124-31. Epub 2008 Dec 15.PMID: 19075068 [PubMed - indexed for MEDLINE]Related articlesFree article

Virologic failure in first-line human immunodeficiency virus therapy with a CCR5 entry inhibitor, aplaviroc, plus a fixed-dose combination of lamivudine-zidovudine: nucleoside reverse transcriptase inhibitor resistance regardless of envelope tropism.

Demarest JF, Amrine-Madsen H, Irlbeck DM, Kitrinos KM; CCR102881 Clinical Study Team.

Antimicrob Agents Chemother. 2009 Mar;53(3):1116-23. Epub 2008 Dec 15.PMID: 19075055 [PubMed - indexed for MEDLINE]Related articlesFree article

Sensitivity of phenotypic susceptibility analyses for nonthymidine nucleoside analogues conferred by K65R or M184V in mixtures with wild-type HIV-1.

Underwood MR, Ross LL, Irlbeck DM, Gerondelis P, Rouse E, St Clair MH, Trinh L, Parkin N, Lanier ER.

J Infect Dis. 2009 Jan 1;199(1):84-8.PMID: 19032103 [PubMed - indexed for MEDLINE]Related articles

Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy.

Johnson JA, Li JF, Wei X, Lipscomb J, Irlbeck D, Craig C, Smith A, Bennett DE, Monsour M, Sandstrom P, Lanier ER, Heneine W.

PLoS Med. 2008 Jul 29;5(7):e158.PMID: 18666824 [PubMed - indexed for MEDLINE]Related articlesFree article

Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.

Irlbeck DM, Amrine-Madsen H, Kitrinos KM, Labranche CC, Demarest JF.

AIDS. 2008 Jul 31;22(12):1425-31.PMID: 18614865 [PubMed - indexed for MEDLINE]Related articles

Salvage therapy with abacavir and other reverse transcriptase inhibitors for human immunodeficiency-associated encephalopathy.

Saavedra-Lozano J, Ramos JT, Sanz F, Navarro ML, de José MI, Martín-Fontelos P, Mellado MJ, Leal JA, Rodriguez C, Luque I, Madison SJ, Irlbeck D, Lanier ER, Ramilo O.

Pediatr Infect Dis J. 2006 Dec;25(12):1142-52.PMID: 17133160 [PubMed - indexed for MEDLINE]Related articles

Long-term results of initial therapy with abacavir and Lamivudine combined with Efavirenz, Amprenavir/Ritonavir, or Stavudine.

Bartlett JA, Johnson J, Herrera G, Sosa N, Rodriguez A, Liao Q, Griffith S, Irlbeck D, Shaefer MS; Clinically Significant Long-Term Antiretroviral Sequential Sequencing Study (CLASS) Team.

J Acquir Immune Defic Syndr. 2006 Nov 1;43(3):284-92.PMID: 16967040 [PubMed - indexed for MEDLINE]Related articles

Patients experiencing early virologic failure on a protease inhibitor- or nonnucleoside reverse transcriptase inhibitor-based initial regimen containing a thymidine analogue and Lamivudine can be successfully treated with a quadruple-nucleoside regimen.

Rodriguez A, Hill-Zabala C, Sloan L, Jefferson T, Yau L, Watson M, Irlbeck D, Shaefer M.

J Acquir Immune Defic Syndr. 2006 Jan 1;41(1):127-9. No abstract available. PMID: 16340487 [PubMed - indexed for MEDLINE]Related articles

Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitors.

Watkins T, Resch W, Irlbeck D, Swanstrom R.

Antimicrob Agents Chemother. 2003 Feb;47(2):759-69.PMID: 12543689 [PubMed - indexed for MEDLINE]Related articlesFree article